1-8 of 8
Douglas G. McNeel
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Multicenter Phase I Trial of a DNA Vaccine Encoding the Androgen Receptor Ligand-binding Domain (pTVG-AR, MVI-118) in Patients with Metastatic Prostate Cancer

Christos E. Kyriakopoulos, Jens C. Eickhoff, Anna C. Ferrari, Michael T. Schweizer, Ellen Wargowski, Brian M. Olson, Douglas G. McNeel
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (19): 5162–5171.
https://doi.org/10.1158/1078-0432.CCR-20-0945
Published: 01 October 2020
View article titled, Multicenter Phase I Trial of a DNA Vaccine Encoding the Androgen Receptor Ligand-binding Domain (pTVG-AR, MVI-118) in Patients with Metastatic Prostate Cancer
Open the PDF for Multicenter Phase I Trial of a DNA Vaccine Encoding the Androgen Receptor Ligand-binding Domain (pTVG-AR, MVI-118) in Patients with Metastatic Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors

Jeffrey S. Miller, Chihiro Morishima, Douglas G. McNeel, Manish R. Patel, Holbrook E.K. Kohrt, John A. Thompson, Paul M. Sondel, Heather A. Wakelee, Mary L. Disis, Judith C. Kaiser, Martin A. Cheever, Howard Streicher, Steven P. Creekmore, Thomas A. Waldmann, Kevin C. Conlon
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (7): 1525–1535.
https://doi.org/10.1158/1078-0432.CCR-17-2451
Published: 02 April 2018
View article titled, A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors
Open the PDF for A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors in another window
Journal Articles

Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma

Toni K. Choueiri, Mayer N. Fishman, Bernard Escudier, David F. McDermott, Charles G. Drake, Harriet Kluger, Walter M. Stadler, Jose Luis Perez-Gracia, Douglas G. McNeel, Brendan Curti, Michael R. Harrison, Elizabeth R. Plimack, Leonard Appleman, Lawrence Fong, Laurence Albiges, Lewis Cohen, Tina C. Young, Scott D. Chasalow, Petra Ross-Macdonald, Shivani Srivastava, Maria Jure-Kunkel, John F. Kurland, Jason S. Simon, Mario Sznol
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2016) 22 (22): 5461–5471.
https://doi.org/10.1158/1078-0432.CCR-15-2839
Published: 14 November 2016
View article titled, Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma
Open the PDF for Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Real-Time Immune Monitoring to Guide Plasmid DNA Vaccination Schedule Targeting Prostatic Acid Phosphatase in Patients with Castration-Resistant Prostate Cancer

Douglas G. McNeel, Jordan T. Becker, Jens C. Eickhoff, Laura E. Johnson, Eric Bradley, Isabel Pohlkamp, Mary Jane Staab, Glenn Liu, George Wilding, Brian M. Olson
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (14): 3692–3704.
https://doi.org/10.1158/1078-0432.CCR-14-0169
Published: 14 July 2014
View article titled, Real-Time Immune Monitoring to Guide Plasmid DNA Vaccination Schedule Targeting Prostatic Acid Phosphatase in Patients with Castration-Resistant Prostate Cancer
Open the PDF for Real-Time Immune Monitoring to Guide Plasmid DNA Vaccination Schedule Targeting Prostatic Acid Phosphatase in Patients with Castration-Resistant Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Treatment of Chronic Lymphocytic Leukemia with a Hypomethylating Agent Induces Expression of NXF2, an Immunogenic Cancer Testis Antigen

Jason A. Dubovsky, Douglas G. McNeel, John J. Powers, John Gordon, Eduardo M. Sotomayor, Javier A. Pinilla-Ibarz
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (10): 3406–3415.
https://doi.org/10.1158/1078-0432.CCR-08-2099
Published: 18 May 2009
View article titled, Treatment of Chronic Lymphocytic Leukemia with a Hypomethylating Agent Induces Expression of NXF2, an Immunogenic Cancer Testis Antigen
Open the PDF for Treatment of Chronic Lymphocytic Leukemia with a Hypomethylating Agent Induces Expression of NXF2, an Immunogenic Cancer Testis Antigen in another window
Includes: Supplementary data
Journal Articles

A Phase I Pharmacokinetic and Pharmacodynamic Correlative Study of the Antisense Bcl-2 Oligonucleotide G3139, in Combination with Carboplatin and Paclitaxel, in Patients with Advanced Solid Tumors

Glenn Liu, Jill Kolesar, Douglas G. McNeel, Catherine Leith, Kathy Schell, Jens Eickhoff, Fred Lee, Anne Traynor, Rebecca Marnocha, Dona Alberti, James Zwiebel, George Wilding
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (9): 2732–2739.
https://doi.org/10.1158/1078-0432.CCR-07-1490
Published: 01 May 2008
View article titled, A Phase I Pharmacokinetic and Pharmacodynamic Correlative Study of the Antisense Bcl-2 Oligonucleotide G3139, in Combination with Carboplatin and Paclitaxel, in Patients with Advanced Solid Tumors
Open the PDF for A Phase I Pharmacokinetic and Pharmacodynamic Correlative Study of the Antisense Bcl-2 Oligonucleotide G3139, in Combination with Carboplatin and Paclitaxel, in Patients with Advanced Solid Tumors in another window
Journal Articles

Phase I Trial of a Monoclonal Antibody Specific for αvβ3 Integrin (MEDI-522) in Patients with Advanced Malignancies, Including an Assessment of Effect on Tumor Perfusion

Douglas G. McNeel, Jens Eickhoff, Fred T. Lee, David M. King, Dona Alberti, James P. Thomas, Andreas Friedl, Jill Kolesar, Rebecca Marnocha, Jennifer Volkman, Jianliang Zhang, Luz Hammershaimb, James A. Zwiebel, George Wilding
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (21): 7851–7860.
https://doi.org/10.1158/1078-0432.CCR-05-0262
Published: 08 November 2005
View article titled, Phase I Trial of a Monoclonal Antibody Specific for α<sub>v</sub>β<sub>3</sub> Integrin (MEDI-522) in Patients with Advanced Malignancies, Including an Assessment of Effect on Tumor Perfusion
Open the PDF for Phase I Trial of a Monoclonal Antibody Specific for α<sub>v</sub>β<sub>3</sub> Integrin (MEDI-522) in Patients with Advanced Malignancies, Including an Assessment of Effect on Tumor Perfusion in another window
Journal Articles

Delayed-Type Hypersensitivity Response Is a Predictor of Peripheral Blood T-Cell Immunity after HER-2/neu Peptide Immunization

Mary L. Disis, Kathy Schiffman, Theodore A. Gooley, Douglas G. McNeel, Kristine Rinn, Keith L. Knutson
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (4): 1347–1350.
Published: 01 April 2000
View article titled, Delayed-Type Hypersensitivity Response Is a Predictor of Peripheral Blood T-Cell Immunity after HER-2/neu Peptide Immunization
Open the PDF for Delayed-Type Hypersensitivity Response Is a Predictor of Peripheral Blood T-Cell Immunity after HER-2/neu Peptide Immunization in another window